The Ohio State University-Clinical Trials Office (OSU-CTO) is currently enrolling cases in a nationwide clinical trial to evaluate safety and efficacy of a novel PI3 Kinase Delta Inhibitor (RV1001) in dogs with naïve or first relapse lymphoma.
The purpose of this study is to monitor dogs for the development of neuropathic pain after SCI, and to test medication effects and inter-observer agreement of a technique to quantify neuropathic pain. We will correlate these results with force plate data from dogs at the same visit.
Kaleigh Peters will tell you that her dog Macy is a typical Doberman. “She’s very smart,” Kaleigh said, adding how the 8-year-old pup loves people, knows lots of tricks, is great with kids and was easy to train.